Arch Therapeutics, Inc.OTCQB
Mon, Aug. 15, 9:25 AM
- Penny stock Arch Therapeutics (OTCQB:ARTH) is up 6% premarket on light volume in response to its announcement of positive results from a first-in-human study of its AC5 Topical Hemostatic Device in skin lesion patients with bleeding wounds.
- Results showed a median time to hemostasis (bleeding has stopped) was 41% faster in the AC5 cohort compared to control. All wounds healed satisfactorily with no serious adverse events reported, including patients on antiplatelet therapy (blood thinners).
- The company plans to included the data in its CE Mark application in Europe.
- AC5 is a synthetic peptide comprised of naturally occurring amino acids. When sprayed onto a wound, it incorporates into the connective tissue forming a barrier to leaking substances, including blood and other body fluids, regardless of clotting ability.
Thu, Jun. 2, 4:18 PM
- Arch Therapeutics (OTCQB:ARTH) enters into subscription agreements with a group of investors to purchase ~$3.4M of the company's securities. Under the terms of the agreements, the investors agreed to buy 9.5M units at $0.36 per unit. Each unit consists of one share of common stock and one five-year Series E Warrant to purchase 3/4 of a share of common at $0.438.
- Today's close was $0.3967.
Mon, Mar. 7, 10:18 AM
- Arch Therapeutics (OTCQB:ARTH +15.6%) commences patient enrollment in its first clinical trial in Europe assessing its AC5 Surgical Hemostatic Device for the control of bleeding. The randomized single-blind study will evaluate the safety and efficacy of AC5 in up to 45 patients undergoing a dermatological procedure. 10 of the patients will be on antiplatelet therapy (blood thinner) during the study period. Each patient will have two skin lesions surgically removed. One of the wounds will be treated with AC5 and the other with control. The primary endpoint is time to hemostasis (bleeding has stopped). Top-line results should be available in late Q3.
- According to the company, AC5 stops bleeding in as little as 10 seconds. It is transparent, conforms to irregular wound geometry and is not sticky or glue-like, making it ideal for laparoscopic procedures.
Jun. 17, 2015, 4:27 PM
Aug. 6, 2014, 10:56 AM
- Arch Therapeutics (OTCQB:ARTH +0.5%) fiscal Q3 results: Revenue: $0; Operating Expenses: $1.1M (+131.7%); Operating Loss: ($1.1) (-131.7%); Net Income: $410.7K (+179.8%); EPS: $0.01 (+116.7%); Quick Assets: $1.8M (+223.4%).
- No guidance given.
Jul. 7, 2014, 7:31 PM
- Arch Therapeutics (ARTH -2.2%) and CFO Alan T. Barber mutually agree to terminate his employment with the company. Consultant Richard E. Davis replaces him. Mr. Davis has been advising Arch since April 2014. He has operated his own consulting firm, Rolling Management, since July 2011. Prior to that he was President, COO and CFO at NMT Medical.